Bioshares Etf Profile

BBP -  USA Etf  

USD 38.51  1.17  3.13%

Market Performance
0 of 100
Odds Of Distress
Less than 1
Bioshares Biotech is selling at 38.51 as of the 17th of May 2022; that is 3.13 percent increase since the beginning of the trading day. The etf's last reported lowest price was 38.51. Bioshares Biotech has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Bioshares Biotech Products are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of April 2022 and ending today, the 17th of May 2022. Click here to learn more.
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Bioshares Biotech is traded on NYSEArca Exchange in the United States. More on Bioshares Biotech Products

Bioshares Biotech Etf Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bioshares Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioshares Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bioshares Biotech generated a negative expected return over the last 90 days
Bioshares Biotech is unlikely to experience financial distress in the next 2 years
The fund holds 97.81% of its assets under management (AUM) in equities
Thematic Classification
Currently Active Investing Idea (view all)
Healthcare Funds
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bioshares Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
DescriptionVirtus LifeSci Biotech Products ETF
Inception Date2014-12-16
BenchmarkLifeSci Biotechnology Products Index
Entity TypeRegulated Investment Company
Asset Under Management12.56 Million
Average Trading Valume1,615.5
Asset TypeEquity
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorVirtus ETF Solutions, LLC
AdvisorVirtus ETF Advisers LLC
CustodianThe Bank of New York Mellon Corporation
DistributorETF Distributors LLC
Portfolio ManagerMatthew B. Brown, Seth Kadushin
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End31-Aug
ExchangeNYSE Arca, Inc.
Number of Constituents51.0
Market MakerVirtu Financial
Total Expense0.79
Management Fee0.79
Nav Price48.93
Two Hundred Day Average46.72
Average Daily Volume In Three Month1.52k
Fifty Two Week Low34.12
As Of Date30th of June 2021
Average Daily Volume Last 10 Day1.22k
Fifty Two Week High55.28
One Month3.18%
Fifty Day Average41.45
Three Month1.93%
Bioshares Biotech Products [BBP] is traded in USA and was established 2014-12-16. The fund is classified under Health category within Virtus family. The entity is thematically classified as Healthcare Funds. Bioshares Biotech currently have 26.68 M in assets under management (AUM). , while the total return for the last 3 years was 6.73%.
Check Bioshares Biotech Probability Of Bankruptcy

Geographic Allocation (%)

Top Bioshares Biotech Products Constituents

Bioshares Biotech Target Price Odds Analysis

What are Bioshares Biotech's target price odds to finish over the current price? Contingent on a normal probability distribution, the odds of Bioshares Biotech jumping above the current price in 90 days from now is about 88.26%. The Bioshares Biotech Products probability density function shows the probability of Bioshares Biotech etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the etf has a beta coefficient of 1.0972 suggesting Bioshares Biotech Products market returns are highly reactive to returns on the market. As the market goes up or down, Bioshares Biotech is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Bioshares Biotech is significantly underperforming DOW.
  Odds Below 38.51HorizonTargetOdds Above 38.51
11.65%90 days
Based on a normal probability distribution, the odds of Bioshares Biotech to move above the current price in 90 days from now is about 88.26 (This Bioshares Biotech Products probability density function shows the probability of Bioshares Etf to fall within a particular range of prices over 90 days) .

Bioshares Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bioshares Biotech market risk premium is the additional return an investor will receive from holding Bioshares Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bioshares Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bioshares Biotech's alpha and beta are two of the key measurements used to evaluate Bioshares Biotech's performance over the market, the standard measures of volatility play an important role as well.

Bioshares Biotech Technical Analysis

The output start index for this execution was zero with a total number of output elements of sixty-one. Bioshares Biotech Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Bioshares Biotech price patterns.

Bioshares Biotech Against Markets

Picking the right benchmark for Bioshares Biotech etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bioshares Biotech etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bioshares Biotech is critical whether you are bullish or bearish towards Bioshares Biotech Products at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bioshares Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Investing Bioshares Biotech Products

You need to understand the risk of investing before taking a position in Bioshares Biotech. The danger of trading Bioshares Biotech Products is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bioshares Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bioshares Biotech. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bioshares Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Bioshares Biotech information on this page should be used as a complementary analysis to other Bioshares Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Bioshares Etf analysis

When running Bioshares Biotech price analysis, check to measure Bioshares Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioshares Biotech is operating at the current time. Most of Bioshares Biotech's value examination focuses on studying past and present price action to predict the probability of Bioshares Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioshares Biotech's price. Additionally, you may evaluate how the addition of Bioshares Biotech to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
The market value of Bioshares Biotech is measured differently than its book value, which is the value of Bioshares that is recorded on the company's balance sheet. Investors also form their own opinion of Bioshares Biotech's value that differs from its market value or its book value, called intrinsic value, which is Bioshares Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioshares Biotech's market value can be influenced by many factors that don't directly affect Bioshares Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioshares Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioshares Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioshares Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.